| Q28075227 | A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism |
| Q37114685 | Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy |
| Q44071363 | Cerebral metabolic changes in early multiple system atrophy: a PET study |
| Q39784721 | Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy |
| Q46750528 | Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease |
| Q36011221 | Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. |
| Q52149073 | Different loss of dopamine transporter according to subtype of multiple system atrophy. |
| Q82029429 | Early detection of Parkinson's disease |
| Q34035765 | FDG PET in the Evaluation of Parkinson's Disease |
| Q35751834 | Functional brain imaging in the differential diagnosis of Parkinson's disease |
| Q36219407 | Functional imaging with positron emission tomography in multiple system atrophy |
| Q42874767 | Motor activation in multiple system atrophy and Parkinson disease |
| Q37185684 | Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes |
| Q38264397 | Neuroimaging biomarkers for Parkinson disease: facts and fantasy |
| Q35817240 | Neuroimaging of Parkinson's disease and atypical parkinsonism |
| Q44060173 | Paradoxical response to apomorphine in a case of atypical parkinsonism |
| Q48659954 | Progressive cerebral atrophy in multiple system atrophy |
| Q43827112 | Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. |
| Q50534006 | Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). |
| Q35692956 | The role of positron emission tomography imaging in movement disorders |
| Q38358021 | The sensitivity and specificity of F-DOPA PET in a movement disorder clinic |